Lorus Completes IND-Enabling Toxicology Studies for Lead Small Molecule Anticancer Drug LOR-253
News Nov 12, 2008
Lorus Therapeutics Inc. has announced the successful completion of toxicology studies for its lead small molecule LOR-253 anticancer drug, formerly known as LT-253. LOR-253 represents a new targeted approach in cancer drug development, by inducing KLF4, a tumor suppressor factor that is reduced in a variety of important cancers.
The GLP, IND-enabling toxicology studies conducted for LOR-253 included maximum tolerated dose studies and repeat-dose toxicity studies in rodents and nonrodents. The data have established the toxicity profile for LOR-253, which will be supportive of a Phase I clinical trial in cancer patients.
Importantly, the study results indicate that LOR-253 is well tolerated at higher dose levels than efficacious dose levels determined from preclinical pharmacology studies.
The toxicology studies were designed to support the dosing regimen and intravenous route of administration for LOR-253 that is planned for a Phase I clinical trial upon filing an investigational new drug (IND) submission with the U.S. FDA.
"The successful completion of the toxicology program for LOR-253 is an important milestone in the development of this novel drug candidate which represents a "first in class" development program", said Dr Aiping Young, Lorus' President and CEO. "We are now one step closer to initiating clinical trials with this exciting compound, which was identified at Lorus using our drug discovery platform".
New Studies Demonstrate Risk Reduction Potential of Heat-Not-Burn Tobacco Products and e-CigarettesNews
Data presented at the Society of Toxicology Annual Meeting (SOT) have demonstrated the potential of two different heat-not-burn tobacco products and e-cigarettes to reduce the risk of smoking-related diseases, in comparison to continued use of conventional cigarettes.READ MORE
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018